21-Aug-2026
Business Wire (Sat, 15-Aug 7:07 AM ET)
PRNewswire (Mon, 10-Aug 8:31 AM ET)
Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders?
PRNewswire (Thu, 9-Jul 7:09 PM ET)
PRNewswire (Thu, 9-Jul 2:43 PM ET)
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 29-Jun 1:59 PM ET)
PRNewswire (Mon, 29-Jun 1:36 PM ET)
PRNewswire (Mon, 29-Jun 10:02 AM ET)
Market Chameleon (Mon, 29-Jun 3:07 AM ET)
PRNewswire (Mon, 29-Jun 6:00 AM ET)
Zymeworks to Acquire Theravance Biopharma, Inc.
Globe Newswire (Mon, 29-Jun 6:00 AM ET)
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Theravance Biopharma - trades on the NASDAQ stock market under the symbol TBPH.
As of August 21, 2026, TBPH stock price climbed to $17.01 with 628,121 million shares trading.
TBPH has a beta of 0.86, meaning it tends to be less sensitive to market movements. TBPH has a correlation of 0.05 to the broad based SPY ETF.
TBPH has a market cap of $883.14 million. This is considered a Small Cap stock.
Last quarter Theravance Biopharma - reported $21 million in Revenue and $.18 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.10.
In the last 3 years, TBPH traded as high as $21.03 and as low as $7.44.
The top ETF exchange traded funds that TBPH belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWO.
TBPH has outperformed the market in the last year with a price return of +24.5% while the SPY ETF gained +21.7%. TBPH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.1% and +0.5%, respectively, while the SPY returned +3.4% and -1.0%, respectively.
TBPH support price is $16.91 and resistance is $16.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TBPH shares will trade within this expected range on the day.